Company / Capital Expenditures
Vertex Pharmaceuticals Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$437.6M
FY2025
5-year range
$200.4M / $437.6M
FY2021-FY2025
Trend
+47.0%
vs FY2024
Sector context
#12 of 194
Health Care
What the data says
Among 194 Health Care companies, Vertex Pharmaceuticals is in the top 6% for capital expenditures. Capital Expenditures has fluctuated over the past 10 years, ranging from $57M in FY2016 to $438M in FY2025.
Based on SEC 10-K filings.
$438M in FY2025 with a 5-year CAGR of +11.0%. Top quartile in the Health Care sector.
Improved from $200M to $438M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +28.8%
- 5-Year CAGR
- +11.0%
- 10-Year CAGR
- -
Sector benchmark
+272.4% above sector average
Key checks
Key Insights
- 5-year CAGR of +11.0%, indicating consistent growth.
- In FY2025, capital expenditures increased 47.0% year-over-year.
- Ranks #12 out of 194 companies in the Health Care sector.
- Lowest capital expenditures in the period was in FY2016.
Company context
Key Data Points
- Strong profit margin: 31.4%
- Strong return on equity: 21.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $437.6M | +47.0% |
| FY2024 | $297.7M | +48.6% |
| FY2023 | $200.4M | -2.1% |
| FY2022 | $204.7M | -12.9% |
| FY2021 | $235.0M | -9.5% |
| FY2020 | $259.8M | +244.6% |
| FY2019 | $75.4M | -21.0% |
| FY2018 | $95.4M | -4.0% |
| FY2017 | $99.4M | +75.8% |
| FY2016 | $56.6M | +24.9% |
As of FY2025 · SEC 10-K · Updated Mar 17, 2026